Heidi Ko: The importance of comprehensive genomic profiling in cancer of unknown primary

Heidi Ko, Medical Director, Medical Affairs, Labcorp Drug Development, shared a post on LinkedIn:

“What an impactful study highlighting the importance of comprehensive genomic profiling (CGP) in cancer of unknown primary (CUP)

CUP accounts for about 2-3% of all metastatic cancers and encompasses diverse cancer types that do not have the usual clinicopathological features suggestive of a primary site. Patients with CUP are traditionally treated with a broad-spectrum of platinum-based chemotherapy.

CUPISCO study showed that patients with non-squamous, poorly differentiated CUP had better outcomes when treated with molecularly guided therapy from CGP than standard platinum-based chemotherapy after achieving initial disease control

Median progression-free survival nearly doubled in the group treated with targeted therapy based on genomic results (8.1 vs. 4.7 months)

CGP should be performed to assess all relevant molecular biomarkers at initial diagnosis for patients with CUP.”

Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study

Authors: Prof Alwin Krämer, Tilmann Bochtler,  Prof Chantal Pauli, Kai-Keen Shiu, Natalie Cook, Juliana Janoski de Menezes, Roberto A Pazo-Cid, Ferran Losa, Debbie GJ Robbrecht,  Jiří Tomášek, Prof Cagatay Arslan, Prof Mustafa Özgüroğlu, Prof Michael Stahl, Frédéric Bigot, Sun Young Kim,   Yoichi Naito, Prof Antoine Italiano, Nasséra Chalabi, Gonzalo Durán-Pacheco, Chantal Michaud, Jeremy Scarato, ∙ Marlene Thomas, Prof Jeffrey S Ross, Prof Holger Moch, Linda Mileshkin.

Source: Heidi Ko/LinkedIn